Advances in molecular and imaging biomarkers in lower-grade gliomas

References

• Ostrom QT, Cioffi G, Waite K, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014–2018. Neuro-Oncology. 2021;23(Supplement_3):iii1–iii105. doi: 10.1093/neuonc/noab200
   PubMed Web of Science ®Google Scholar
• Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360:765–773. doi: 10.1056/NEJMoa0808710
   PubMed Web of Science ®Google Scholar
• Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739–744. doi: 10.1038/nature08617
   PubMed Web of Science ®Google Scholar
• Sanson M, Marie Y, Paris S, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 2009;27(25):4150–4154. doi: 10.1200/JCO.2009.21.9832
   PubMed Web of Science ®Google Scholar
• Turcan S, Rohle D, Goenka A, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 2012;483(7390):479–483. doi: 10.1038/nature10866
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network, Brat DJ, Verhaak RGW, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 2015;372:2481–2498.
   PubMed Web of Science ®Google Scholar
• Eckel-Passow JE, Lachance DH, Molinaro AM, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med. 2015;372(26):2499–2508. doi: 10.1056/NEJMoa1407279
   PubMed Web of Science ®Google Scholar
• Labussière M, Idbaih A, Wang X-W, et al. All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology. 2010;74(23):1886–1890. doi: 10.1212/WNL.0b013e3181e1cf3a
   PubMed Web of Science ®Google Scholar
• Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–820. doi: 10.1007/s00401-016-1545-1
   PubMed Web of Science ®Google Scholar
• Schiff D, Van den Bent M, Vogelbaum MA, et al. Recent developments and future directions in adult lower-grade gliomas: society for neuro-oncology (SNO) and European association of Neuro-oncology (EANO) consensus. Neuro Oncol. 2019;21(7):837–853. doi: 10.1093/neuonc/noz033
   PubMed Web of Science ®Google Scholar
• Aoki K, Nakamura H, Suzuki H, et al. Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro Oncol. 2018;20(1):66–77. doi: 10.1093/neuonc/nox132
   PubMed Web of Science ®Google Scholar
• Reuss DE, Kratz A, Sahm F, et al. Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. Acta Neuropathol. 2015;130(3):407–417. doi: 10.1007/s00401-015-1454-8
   PubMed Web of Science ®Google Scholar
• Aibaidula A, Chan A-Y, Shi Z, et al. Adult IDH wild-type lower-grade gliomas should be further stratified. Neuro-Oncology. 2017;19(10):1327–1337. doi: 10.1093/neuonc/nox078
   PubMed Web of Science ®Google Scholar
• Hasselblatt M, Jaber M, Reuss D, et al. Diffuse astrocytoma, IDH-Wildtype: a dissolving diagnosis. J Neuropathol Exp Neurol. 2018;77(6):422–425. doi: 10.1093/jnen/nly012
   PubMed Web of Science ®Google Scholar
• Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231–1251. doi: 10.1093/neuonc/noab106
   PubMed Web of Science ®Google Scholar
• Berzero G, Di Stefano AL, Ronchi S, et al. IDH-wildtype lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification. Neuro Oncol. 2021;23(6):955–966. doi: 10.1093/neuonc/noaa258
   PubMed Web of Science ®Google Scholar
• Rudà R, Bruno F, Ius T, et al. IDH wild-type grade 2 diffuse astrocytomas: prognostic factors and impact of treatments within molecular subgroups. Neuro Oncol. 2022;24(5):809–820. doi: 10.1093/neuonc/noab239
   PubMed Web of Science ®Google Scholar
• Xu W, Yang H, Liu Y, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011;19(1):17–30. doi: 10.1016/j.ccr.2010.12.014
   PubMed Web of Science ®Google Scholar
• Chowdhury R, Yeoh KK, Tian Y-M, et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep. 2011;12(5):463–469. doi: 10.1038/embor.2011.43
   PubMed Web of Science ®Google Scholar
• Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010;17(5):510–522. doi: 10.1016/j.ccr.2010.03.017
   PubMed Web of Science ®Google Scholar
• Turcan S, Makarov V, Taranda J, et al. Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence. Nat Genet. 2018;50(1):62–72. doi: 10.1038/s41588-017-0001-z
   PubMed Web of Science ®Google Scholar
• Barthel FP, Wesseling P, Verhaak RGW. Reconstructing the molecular life history of gliomas. Acta Neuropathol. 2018;135(5):649–670. doi: 10.1007/s00401-018-1842-y
   PubMed Web of Science ®Google Scholar
• Picca A, Berzero G, Di Stefano AL, et al. The clinical use of IDH1 and IDH2 mutations in gliomas. Expert Rev Mol Diagn. 2018;18(12):1041–1051. doi: 10.1080/14737159.2018.1548935
   PubMed Web of Science ®Google Scholar
• Reifenberger J, Reifenberger G, Liu L, et al. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol. 1994;145(5):1175–1190.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Aoki K, Chiba K, et al. Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet. 2015;47(5):458–468. doi: 10.1038/ng.3273
   PubMed Web of Science ®Google Scholar
• Picca A, Berzero G, Sanson M. Current therapeutic approaches to diffuse grade II and III gliomas. Ther Adv Neurol Disord. 2018;11:1756285617752039. doi: 10.1177/1756285617752039
   Web of Science ®Google Scholar
• Appay R, Dehais C, Maurage C-A, et al. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. Neuro Oncol. 2019;21(Supplement_3):iii1–iii1. doi: 10.1093/neuonc/noz126.000
   Google Scholar
• Gleize V, Alentorn A, Connen de Kérillis L, et al. CIC inactivating mutations identify aggressive subset of 1p19q codeleted gliomas. Ann Neurol. 2015;78(3):355–374. doi: 10.1002/ana.24443
   PubMed Web of Science ®Google Scholar
• Louis DN, Giannini C, Capper D, et al. cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant. Acta Neuropathol. 2018;135:639–642. doi: 10.1007/s00401-018-1826-y
   PubMed Web of Science ®Google Scholar
• Shirahata M, Ono T, Stichel D, et al. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Acta Neuropathol. 2018;136(1):153–166. doi: 10.1007/s00401-018-1849-4
   PubMed Web of Science ®Google Scholar
• Reis GF, Pekmezci M, Hansen HM, et al. CDKN2A loss is associated with shortened overall survival in lower-grade (world Health organization grades II–III) astrocytomas. J Neuropathol Exp Neurol. 2015;74(5):442–452. doi: 10.1097/NEN.0000000000000188
   PubMed Web of Science ®Google Scholar
• Brat DJ, Aldape K, Colman H, et al. cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol. 2020;139(3):603–608. doi: 10.1007/s00401-020-02127-9
   PubMed Web of Science ®Google Scholar
• Tesileanu CMS, Dirven L, Wijnenga MMJ, et al. Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria. Neuro Oncol. 2020;22(4):515–523. doi: 10.1093/neuonc/noz200
   PubMed Web of Science ®Google Scholar
• Muench A, Teichmann D, Spille D, et al. A novel type of IDH wild-type glioma characterized by gliomatosis cerebri-like growth pattern, TERT promoter mutation, and distinct epigenetic profile. Am J Surg Pathol. [Internet]. 9900. Available from: https://journals.lww.com/ajsp/fulltext/9900/a_novel_type_of_idh_wild_type_glioma_characterized.233.aspx
   Google Scholar
• Ceccarelli M, Barthel FP, Malta TM, et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell. 2016;164(3):550–563. doi: 10.1016/j.cell.2015.12.028
   PubMed Web of Science ®Google Scholar
• Picca A, Berzero G, Bielle F, et al. FGFR1 actionable mutations, molecular specificities, and outcome of adult midline gliomas. Neurology. 2018;90(23):e2086–e2094. doi: 10.1212/WNL.0000000000005658
   PubMed Web of Science ®Google Scholar
• Weller M, van den Bent M, Preusser M, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2021;18(3):170–186. doi: 10.1038/s41571-020-00447-z
   PubMed Web of Science ®Google Scholar
• Tesileanu CMS, Sanson M, Wick W, et al. Temozolomide and radiotherapy versus radiotherapy alone in patients with glioblastoma, IDH-wildtype: post hoc analysis of the EORTC randomized phase III CATNON trial. Clin Cancer Res. 2022;28(12):2527–2535. doi: 10.1158/1078-0432.CCR-21-4283
   PubMed Web of Science ®Google Scholar
• Fujimoto K, Arita H, Satomi K, et al. TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma. Acta Neuropathol. 2021;142(2):323–338. doi: 10.1007/s00401-021-02337-9
   PubMed Web of Science ®Google Scholar
• Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery. 2008;62(4):753–766. discussion 264-266. doi: 10.1227/01.neu.0000318159.21731.cf
   PubMed Web of Science ®Google Scholar
• Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. JCO. 2008;26(8):1338–1345. doi: 10.1200/JCO.2007.13.9337
   PubMed Web of Science ®Google Scholar
• Beiko J, Suki D, Hess KR, et al. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol. 2014;16(1):81–91. doi: 10.1093/neuonc/not159
   PubMed Web of Science ®Google Scholar
• Jakola AS, Skjulsvik AJ, Myrmel KS, et al. Surgical resection versus watchful waiting in low-grade gliomas. Ann Oncol. 2017;28(8):1942–1948. doi: 10.1093/annonc/mdx230
   PubMed Web of Science ®Google Scholar
• Kavouridis VK, Boaro A, Dorr J, et al. Contemporary assessment of extent of resection in molecularly defined categories of diffuse low-grade glioma: a volumetric analysis. J Neurosurg. 2019;1–11. doi: 10.3171/2019.6.JNS19972
   PubMed Web of Science ®Google Scholar
• Wijnenga MMJ, French PJ, Dubbink HJ, et al. The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis. Neuro Oncol. 2018;20(1):103–112. doi: 10.1093/neuonc/nox176
   PubMed Web of Science ®Google Scholar
• Jakola AS, Pedersen LK, Skjulsvik AJ, et al. The impact of resection in IDH-mutant WHO grade 2 gliomas: a retrospective population-based parallel cohort study. Journal Of Neurosurgery. 2022;137(5):1321–1328. doi: 10.3171/2022.1.JNS212514
   Web of Science ®Google Scholar
• Hervey-Jumper SL, Zhang Y, Phillips JJ, et al. Interactive effects of molecular, therapeutic, and patient factors on outcome of diffuse low-grade glioma. JCO. 2023;41:2029–2042. doi: 10.1200/JCO.21.02929
   PubMed Web of Science ®Google Scholar
• Harary M, Kavouridis VK, Torre M, et al. Predictors and early survival outcomes of maximal resection in WHO grade II 1p/19q-codeleted oligodendrogliomas. Neuro Oncol. 2020;22:369–380. doi: 10.1093/neuonc/noz168
   PubMed Web of Science ®Google Scholar
• Patel SH, Bansal AG, Young EB, et al. Extent of surgical resection in lower-grade gliomas: differential impact based on molecular subtype. AJNR Am J Neuroradiol. 2019;40(7):1149–1155. doi: 10.3174/ajnr.A6102
   PubMed Web of Science ®Google Scholar
• Rossi M, Gay L, Ambrogi F, et al. Association of supratotal resection with progression-free survival, malignant transformation, and overall survival in lower-grade gliomas. Neuro Oncol. 2021;23(5):812–826. doi: 10.1093/neuonc/noaa225
   PubMed Web of Science ®Google Scholar
• Rossi M, Ambrogi F, Gay L, et al. Is supratotal resection achievable in low-grade gliomas? Feasibility, putative factors, safety, and functional outcome. Journal Of Neurosurgery. 2019;132(6):1692–1705. doi: 10.3171/2019.2.JNS183408
   PubMed Web of Science ®Google Scholar
• Mandonnet E, Duffau H, Bauchet L. A new tool for grade II glioma studies: plotting cumulative time with quality of life versus time to malignant transformation. J Neurooncol. 2012;106(1):213–215. doi: 10.1007/s11060-011-0659-5
   PubMed Web of Science ®Google Scholar
• Duffau H, Mandonnet E. The “onco-functional balance” in surgery for diffuse low-grade glioma: integrating the extent of resection with quality of life. Acta Neurochir. 2013;155(6):951–957. doi: 10.1007/s00701-013-1653-9
   PubMed Web of Science ®Google Scholar
• Mandonnet E, Duffau H. An attempt to conceptualize the individual onco-functional balance: why a standardized treatment is an illusion for diffuse low-grade glioma patients. Crit Rev Oncol Hematol. 2018;122:83–91. doi: 10.1016/j.critrevonc.2017.12.008
   PubMed Web of Science ®Google Scholar
• De Witt Hamer PC, Klein M, Hervey-Jumper SL, et al. Functional outcomes and Health-related quality of life following glioma surgery. Neurosurg. 2021;88(4):720–732. doi: 10.1093/neuros/nyaa365
   PubMed Web of Science ®Google Scholar
• Englot DJ, Berger MS, Barbaro NM, et al. Predictors of seizure freedom after resection of supratentorial low-grade gliomas. A review. J Neurosurg. 2011;115(2):240–244. doi: 10.3171/2011.3.JNS1153
   PubMed Web of Science ®Google Scholar
• Ng S, Herbet G, Moritz-Gasser S, et al. Return to work following surgery for incidental diffuse low-grade glioma: a prospective series with 74 patients. Neurosurg. 2020;87(4):720–729. doi: 10.1093/neuros/nyz513
   PubMed Web of Science ®Google Scholar
• Buckner JC, Shaw EG, Pugh SL, et al. Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. N Engl J Med. 2016;374(14):1344–1355. doi: 10.1056/NEJMoa1500925
   PubMed Web of Science ®Google Scholar
• Lassman AB, Hoang-Xuan K, Polley M-Y, et al. Joint final report of EORTC 26951 and RTOG 9402: phase III trials with procarbazine, lomustine, and vincristine chemotherapy for anaplastic oligodendroglial tumors. JCO. 2022;40(23):2539–2545. doi: 10.1200/JCO.21.02543
   PubMed Web of Science ®Google Scholar
• Van Den Bent MJ, Erridge S, Vogelbaum MA, et al. Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion. JCO. 2019;37:2000–2000. doi: 10.1200/JCO.2019.37.15_suppl.2000
   Web of Science ®Google Scholar
• Bell EH, Zhang P, Shaw EG, et al. Comprehensive Genomic analysis in NRG oncology/RTOG 9802: a phase III trial of radiation versus radiation plus procarbazine, lomustine (CCNU), and vincristine in high-risk low-grade glioma. JCO. 2020;38(29):3407–3417. doi: 10.1200/JCO.19.02983
   PubMed Web of Science ®Google Scholar
• Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol. 2014;32(8):783–790. doi: 10.1200/JCO.2013.49.3726
   PubMed Web of Science ®Google Scholar
• Baumert BG, Hegi ME, van den Bent MJ, et al. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2016;17(11):1521–1532. doi: 10.1016/S1470-2045(16)30313-8
   PubMed Web of Science ®Google Scholar
• Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2013;31(3):337–343. doi: 10.1200/JCO.2012.43.2674
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Brandes AA, Taphoorn MJB, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2013;31(3):344–350. doi: 10.1200/JCO.2012.43.2229
   PubMed Web of Science ®Google Scholar
• Jaeckle KA, Ballman KV, van den Bent M, et al. CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design. Neuro Oncol. 2021;23(3):457–467. doi: 10.1093/neuonc/noaa168
   PubMed Web of Science ®Google Scholar
• Rudà R, Pellerino A, Pace A, et al. Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian association for Neuro-oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016. J Neurooncol. 2019;145(1):115–123. doi: 10.1007/s11060-019-03277-x
   PubMed Web of Science ®Google Scholar
• Wahl M, Phillips JJ, Molinaro AM, et al. Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide. Neuro Oncol. 2017;19:242–251. doi: 10.1093/neuonc/now176
   PubMed Web of Science ®Google Scholar
• Wick A, Sander A, Koch M, et al. Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q – IMPROVE CODEL: the NOA-18 trial. BMC Cancer. 2022;22(1):645. doi: 10.1186/s12885-022-09720-z
   PubMed Web of Science ®Google Scholar
• Mellinghoff IK, Ellingson BM, Touat M, et al. Ivosidenib in isocitrate dehydrogenase 1-mutated advanced glioma. JCO. 2020;38(29):3398–3406. doi: 10.1200/JCO.19.03327
   PubMed Web of Science ®Google Scholar
• Mellinghoff IK, Penas-Prado M, Peters KB, et al. Vorasidenib, a dual inhibitor of mutant IDH1/2, in recurrent or progressive glioma; results of a first-in-human phase I trial. Clin Cancer Res. 2021;27(16):4491–4499. doi: 10.1158/1078-0432.CCR-21-0611
   PubMed Web of Science ®Google Scholar
• Mellinghoff IK, Lu M, Wen PY, et al. Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial. Nat Med. 2023;29(3):615–622. doi: 10.1038/s41591-022-02141-2
   PubMed Web of Science ®Google Scholar
• Mellinghoff IK, Van Den Bent MJ, Blumenthal DT, et al. Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma. N Engl J Med. 2023;389(7):589–601. doi: 10.1056/NEJMoa2304194
   PubMed Web of Science ®Google Scholar
• Platten M, Bunse L, Wick W. Emerging targets for anticancer vaccination: IDH. ESMO Open. 2021;6(4):100214. doi: 10.1016/j.esmoop.2021.100214
   PubMed Web of Science ®Google Scholar
• Schumacher T, Bunse L, Pusch S, et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature. 2014;512(7514):324–327. doi: 10.1038/nature13387
   PubMed Web of Science ®Google Scholar
• Pellegatta S, Valletta L, Corbetta C, et al. Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma. Acta Neuropathol Commun. 2015;3(1):4. doi: 10.1186/s40478-014-0180-0
   PubMed Web of Science ®Google Scholar
• Platten M, Bunse L, Wick A, et al. A vaccine targeting mutant IDH1 in newly diagnosed glioma. Nature. 2021;592:463–468. doi: 10.1038/s41586-021-03363-z
   PubMed Web of Science ®Google Scholar
• Mohan A, Peters K, Hotchkiss K, et al. IMMU-06. Targeting idh1 mutant grade II recurrent gliomas using a peptide vaccination strategy. Neurooncol Adv. 2021;3(Supplement_4):iv5–iv6. doi: 10.1093/noajnl/vdab112.019
   Google Scholar
• Bunse L, Rupp A-K, Poschke I, et al. AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas. Neurol Res Pract. 2022;4(1):20. doi: 10.1186/s42466-022-00184-x
   PubMedGoogle Scholar
• Picca A, Finocchiaro G. Deciphering diffuse glioma immune microenvironment as a key to improving immunotherapy results. Curr Opin Oncol. 2022;34(6):653–660. doi: 10.1097/CCO.0000000000000895
   PubMed Web of Science ®Google Scholar
• Richard Q, Laurenge A, Mallat M, et al. New insights into the immune TME of adult-type diffuse gliomas. Curr Opin Neurol. 2022;35(6):794–802. doi: 10.1097/WCO.0000000000001112
   PubMed Web of Science ®Google Scholar
• Turcan S, Fabius AWM, Borodovsky A, et al. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT inhibitor decitabine. Oncotarget. 2013;4(10):1729–1736. doi: 10.18632/oncotarget.1412
   PubMed Web of Science ®Google Scholar
• Borodovsky A, Salmasi V, Turcan S, et al. 5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft. Oncotarget. 2013;4(10):1737–1747. doi: 10.18632/oncotarget.1408
   PubMed Web of Science ®Google Scholar
• Yamashita AS, da Costa Rosa M, Borodovsky A, et al. Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide. Neuro Oncol. 2019;21(2):189–200. doi: 10.1093/neuonc/noy146
   PubMed Web of Science ®Google Scholar
• da Costa Rosa M, Yamashita AS, Riggins GJ. Evaluation of a DNA demethylating agent in combination with all-trans retinoic acid for IDH1-mutant gliomas. Neuro Oncol. 2022;24(5):711–723. doi: 10.1093/neuonc/noab263
   PubMed Web of Science ®Google Scholar
• Federici L, Capelle L, Annereau M, et al. 5-azacitidine in patients with IDH1/2-mutant recurrent glioma. Neuro Oncol. 2020;22(8):1226–1228. doi: 10.1093/neuonc/noaa074
   PubMed Web of Science ®Google Scholar
• Sulkowski PL, Corso CD, Robinson ND, et al. 2-hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity. Sci Transl Med. 2017;9(375):eaal2463. doi: 10.1126/scitranslmed.aal2463
   PubMed Web of Science ®Google Scholar
• Byrum AK, Vindigni A, Mosammaparast N. Defining and modulating ‘BRCAness’. Trends In Cell Biology. 2019;29(9):740–751. doi: 10.1016/j.tcb.2019.06.005
   PubMed Web of Science ®Google Scholar
• Ducray F, Sanson M, Chinot O, et al. KS02.4.A Olaparib in Recurrent IDH-mutant High-Grade Glioma (OLAGLI). Neuro Oncol. 2021;23(Supplement_2):ii4. doi: 10.1093/neuonc/noab180.011
   Google Scholar
• Fanucci K, Pilat MJ, Shyr D, et al. Multicenter phase II trial of the PARP inhibitor olaparib in recurrent IDH1- and IDH2-mutant glioma. Cancer Res Commun. 2023;3(2):192–201. doi: 10.1158/2767-9764.CRC-22-0436
   PubMedGoogle Scholar
• Ramos R, Climans SA, Adile A, et al. Combination olaparib and durvalumab for patients with recurrent IDH-mutated gliomas. JCO. 2021;39(15_suppl):e14026–e14026. doi: 10.1200/JCO.2021.39.15_suppl.e14026
   Web of Science ®Google Scholar
• Tateishi K, Wakimoto H, Iafrate AJ, et al. Extreme vulnerability of IDH1 mutant cancers to NAD+ depletion. Cancer Cell. 2015;28(6):773–784. doi: 10.1016/j.ccell.2015.11.006
   PubMed Web of Science ®Google Scholar
• Seltzer MJ, Bennett BD, Joshi AD, et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res. 2010;70(22):8981–8987. doi: 10.1158/0008-5472.CAN-10-1666
   PubMed Web of Science ®Google Scholar
• Manfrini E, Smits M, Thust S, et al. From research to clinical practice: a European neuroradiological survey on quantitative advanced MRI implementation. Eur Radiol. 2021;31(8):6334–6341. doi: 10.1007/s00330-020-07582-2
   PubMed Web of Science ®Google Scholar
• Lasocki A, Anjari M, Ӧrs Kokurcan S, et al. Conventional MRI features of adult diffuse glioma molecular subtypes: a systematic review. Neuroradiology. 2021;63(3):353–362. doi: 10.1007/s00234-020-02532-7
   PubMed Web of Science ®Google Scholar
• Hirschler L, Sollmann N, Schmitz‐Abecassis B, et al. Advanced MR techniques for preoperative glioma characterization: part 1. Magn Reson Imaging. 2023;57(6):1655–1675. doi: 10.1002/jmri.28662
   Google Scholar
• Hangel G, Schmitz‐Abecassis B, Sollmann N, et al. Advanced MR techniques for preoperative glioma characterization: part 2. Magn Reson Imaging. 2023;57(6):1676–1695. doi: 10.1002/jmri.28663
   Google Scholar
• Clement P, Booth T, Borovečki F, et al. GliMR: cross-border collaborations to promote advanced MRI biomarkers for glioma. J Med Biol Eng. 2021;41(2):115–125. doi: 10.1007/s40846-020-00582-z
   PubMed Web of Science ®Google Scholar
• Romeo V, Stanzione A, Ugga L, et al. A critical appraisal of the quality of glioma imaging guidelines using the AGREE II tool: a EuroAIM initiative. Front Oncol. 2019;9:472. doi: 10.3389/fonc.2019.00472
   PubMed Web of Science ®Google Scholar
• Lasocki A, Abdalla G, Chow G, et al. Imaging features associated with H3 K27-altered and H3 G34-mutant gliomas: a narrative systematic review. Cancer Imaging. 2022;22(1):63. doi: 10.1186/s40644-022-00500-3
   PubMed Web of Science ®Google Scholar
• Wasserman JK, Nicholas G, Yaworski R, et al. Radiological and pathological features associated with IDH1-R132H mutation status and early mortality in newly diagnosed anaplastic astrocytic tumours. Scheurer M, editor. PLoS One. 2015;10(4):e0123890. doi: 10.1371/journal.pone.0123890
   PubMed Web of Science ®Google Scholar
• Suh CH, Kim HS, Jung SC, et al. Imaging prediction of isocitrate dehydrogenase (IDH) mutation in patients with glioma: a systemic review and meta-analysis. Eur Radiol. 2019;29(2):745–758. doi: 10.1007/s00330-018-5608-7
   PubMed Web of Science ®Google Scholar
• Natsumeda M, Igarashi H, Gabdulkhaev R, et al. Detection of 2-hydroxyglutarate by 3.0-tesla magnetic resonance spectroscopy in gliomas with rare IDH mutations: making sense of “false-positive” cases. Diagnostics . 2021;11(11):2129. doi: 10.3390/diagnostics11112129
   Web of Science ®Google Scholar
• Liserre R, Branzoli F, Pagani F, et al. Exceptionally rare IDH1-mutant adult medulloblastoma with concurrent GNAS mutation revealed by in vivo magnetic resonance spectroscopy and deep sequencing. acta neuropathol commun. Acta Neuropathol Commun. 2023;11(1):47. doi: 10.1186/s40478-023-01531-y
   PubMed Web of Science ®Google Scholar
• Smits M. MRI biomarkers in neuro-oncology. Nat Rev Neurol. 2021;17(8):486–500. doi: 10.1038/s41582-021-00510-y
   PubMed Web of Science ®Google Scholar
• Pope WB, Prins RM, Albert Thomas M, et al. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. J Neurooncol. 2012;107(1):197–205. doi: 10.1007/s11060-011-0737-8
   PubMed Web of Science ®Google Scholar
• Kim H, Kim S, Lee HH, et al. In-Vivo Proton Magnetic Resonance Spectroscopy of 2-Hydroxyglutarate in Isocitrate Dehydrogenase-Mutated Gliomas: A Technical Review for Neuroradiologists. Korean J Radiol. 2016;17(5):620. doi: 10.3348/kjr.2016.17.5.620
   PubMed Web of Science ®Google Scholar
• Shams Z, van der Kemp WJM, Emir U, et al. Comparison of 2-hydroxyglutarate detection with sLASER and MEGA-sLASER at 7T. Front Neurol. 2021;12:718423. doi: 10.3389/fneur.2021.718423
   PubMed Web of Science ®Google Scholar
• Suh CH, Kim HS, Paik W, et al. False-Positive Measurement at 2-Hydroxyglutarate MR Spectroscopy in Isocitrate Dehydrogenase Wild-Type Glioblastoma: A Multifactorial Analysis. Radiology. 2019;291(3):752–762. doi: 10.1148/radiol.2019182200
   PubMed Web of Science ®Google Scholar
• Branzoli F, Di Stefano AL, Capelle L, et al. Highly specific determination of IDH status using edited in vivo magnetic resonance spectroscopy. Neuro Oncol. 2018;20(7):907–916. doi: 10.1093/neuonc/nox214
   PubMed Web of Science ®Google Scholar
• Di Stefano AL, Nichelli L, Berzero G, et al. In vivo 2-hydroxyglutarate monitoring with edited MR spectroscopy for the follow-up of IDH-Mutant diffuse gliomas: the IDASPE prospective study. Neurology. 2023;100(1):e94–e106. doi: 10.1212/WNL.0000000000201137
   PubMed Web of Science ®Google Scholar
• Branzoli F, Marjańska M. Magnetic resonance spectroscopy of isocitrate dehydrogenase mutated gliomas: current knowledge on the neurochemical profile. Curr Opin Neurol. 2020;33(4):413–421. doi: 10.1097/WCO.0000000000000833
   PubMed Web of Science ®Google Scholar
• Andronesi OC, Arrillaga-Romany IC, Ly KI, et al. Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate. Nat Commun. 2018;9(1):1474. doi: 10.1038/s41467-018-03905-6
   PubMedGoogle Scholar
• Bolan PJ, Branzoli F, Di Stefano AL, et al. Automated acquisition planning for magnetic resonance spectroscopy in brain Cancer. Med Image Comput Comput Assist Interv. 2020;12267:730–739.
   PubMedGoogle Scholar
• Choi I-Y, Andronesi OC, Barker P, et al. Spectral editing in 1 H magnetic resonance spectroscopy: Experts’ consensus recommendations. NMR Biomed. 2021;34(5):e4411. doi: 10.1002/nbm.4411
   PubMed Web of Science ®Google Scholar
• Near J, Harris AD, Juchem C, et al. Preprocessing, analysis and quantification in single-voxel magnetic resonance spectroscopy: experts’ consensus recommendations. NMR Biomed. 2021;34(5):e4257. doi: 10.1002/nbm.4257
   PubMed Web of Science ®Google Scholar
• Tan WL, Huang WY, Yin B, et al. Can diffusion tensor imaging noninvasively detect IDH1 gene mutations in astrogliomas? A retrospective study of 112 cases. Am J Neuroradiol. 2014;35(5):920–927. doi: 10.3174/ajnr.A3803
   PubMed Web of Science ®Google Scholar
• Aliotta E, Nourzadeh H, Batchala PP, et al. Molecular subtype classification in lower-grade glioma with accelerated DTI. AJNR Am J Neuroradiol. 2019;ajnr;ajnr.A6162v1. doi: 10.3174/ajnr.A6162
   PubMed Web of Science ®Google Scholar
• Chu J, Song Y, Tian Y, et al. Diffusion kurtosis imaging in evaluating gliomas: different region of interest selection methods on time efficiency, measurement repeatability, and diagnostic ability. Eur Radiol. 2021;31(2):729–739. doi: 10.1007/s00330-020-07204-x
   PubMed Web of Science ®Google Scholar
• Iima M, Le Bihan D. Clinical Intravoxel Incoherent Motion and Diffusion MR Imaging: Past, Present, and Future. Radiology. 2016;278(1):13–32. doi: 10.1148/radiol.2015150244
   PubMed Web of Science ®Google Scholar
• Tan Y, Zhang H, Wang X, et al. Comparing the value of DKI and DTI in detecting isocitrate dehydrogenase genotype of astrocytomas. Clin Radiol. 2019;74(4):314–320. doi: 10.1016/j.crad.2018.12.004
   PubMed Web of Science ®Google Scholar
• Zhao J, Wang Y-L, Li X-B, et al. Comparative analysis of the diffusion kurtosis imaging and diffusion tensor imaging in grading gliomas, predicting tumour cell proliferation and IDH-1 gene mutation status. J Neurooncol. 2019;141(1):195–203. doi: 10.1007/s11060-018-03025-7
   PubMed Web of Science ®Google Scholar
• Gu T, Yang T, Huang J, et al. Evaluation of gliomas peritumoral diffusion and prediction of IDH1 mutation by IVIM-DWI. Aging. 2021;13(7):9948–9959. doi: 10.18632/aging.202751
   PubMedGoogle Scholar
• Guo H, Liu J, Hu J, et al. Diagnostic performance of gliomas grading and IDH status decoding a comparison between 3D amide proton transfer APT and four diffusion‐weighted MRI models. Magn Reson Imaging. 2022;56(6):1834–1844. doi: 10.1002/jmri.28211
   Web of Science ®Google Scholar
• Thust SC, Heiland S, Falini A, et al. Glioma imaging in Europe: a survey of 220 centres and recommendations for best clinical practice. Eur Radiol. 2018;28(8):3306–3317. doi: 10.1007/s00330-018-5314-5
   PubMed Web of Science ®Google Scholar
• Lev MH, Ozsunar Y, Henson JW, et al. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. AJNR Am J Neuroradiol. 2004;25(2):214–221.
   PubMed Web of Science ®Google Scholar
• Smits M. Imaging of oligodendroglioma. BJR. 2016;89(1060):20150857. doi: 10.1259/bjr.20150857
   Google Scholar
• Siakallis L, Topriceanu C-C, Panovska-Griffiths J, et al. The role of DSC MR perfusion in predicting IDH mutation and 1p19q codeletion status in gliomas: meta-analysis and technical considerations. Neuroradiology. 2023;65(7):1111–1126. doi: 10.1007/s00234-023-03154-5
   PubMed Web of Science ®Google Scholar
• van Santwijk L, Kouwenberg V, Meijer F, et al. A systematic review and meta-analysis on the differentiation of glioma grade and mutational status by use of perfusion-based magnetic resonance imaging. Insights Imaging. 2022;13(1):102. doi: 10.1186/s13244-022-01230-7
   PubMed Web of Science ®Google Scholar
• Yoo R-E, Yun TJ, Hwang I, et al. Arterial spin labeling perfusion-weighted imaging aids in prediction of molecular biomarkers and survival in glioblastomas. Eur Radiol. 2020;30(2):1202–1211. doi: 10.1007/s00330-019-06379-2
   PubMed Web of Science ®Google Scholar
• Yang Y, He MZ, Li T, et al. MRI combined with PET-CT of different tracers to improve the accuracy of glioma diagnosis: a systematic review and meta-analysis. Neurosurg Rev. 2019;42(2):185–195. doi: 10.1007/s10143-017-0906-0
   PubMed Web of Science ®Google Scholar
• Suchorska B, Giese A, Biczok A, et al. Identification of time-to-peak on dynamic 18F-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma. Neuro Oncol. 2018;20(2):279–288. doi: 10.1093/neuonc/nox153
   PubMed Web of Science ®Google Scholar
• Kunz M, Albert NL, Unterrainer M, et al. Dynamic 18F-FET PET is a powerful imaging biomarker in gadolinium-negative gliomas. Neuro Oncol. 2019;21(2):274–284. doi: 10.1093/neuonc/noy098
   PubMed Web of Science ®Google Scholar
• Law I, Albert NL, Arbizu J, et al. Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0. Eur J Nucl Med Mol Imaging. 2019;46(3):540–557. doi: 10.1007/s00259-018-4207-9
   PubMed Web of Science ®Google Scholar
• Jiang S, Zou T, Eberhart CG, et al. Predicting IDH mutation status in grade II gliomas using amide proton transfer-weighted (APTw) MRI: predicting IDH status with APTw MRI. Magn Reson Med. 2017;78(3):1100–1109. doi: 10.1002/mrm.26820
   PubMed Web of Science ®Google Scholar
• Paech D, Windschuh J, Oberhollenzer J, et al. Assessing the predictability of IDH mutation and MGMT methylation status in glioma patients using relaxation-compensated multipool CEST MRI at 7.0 T. Neuro Oncol. 2018;20(12):1661–1671. doi: 10.1093/neuonc/noy073
   PubMed Web of Science ®Google Scholar
• Joo B, Han K, Ahn SS, et al. Amide proton transfer imaging might predict survival and IDH mutation status in high-grade glioma. Eur Radiol. 2019;29(12):6643–6652. doi: 10.1007/s00330-019-06203-x
   PubMed Web of Science ®Google Scholar
• Xu Z, Ke C, Liu J, et al. Diagnostic performance between MR amide proton transfer (APT) and diffusion kurtosis imaging (DKI) in glioma grading and IDH mutation status prediction at 3 T. Eur J Radiol. 2021;134:109466. doi: 10.1016/j.ejrad.2020.109466
   PubMed Web of Science ®Google Scholar
• Zhou J, Zaiss M, Knutsson L, et al. Review and consensus recommendations on clinical APT ‐weighted imaging approaches at 3T: application to brain tumors. Magnetic Resonance In Med. 2022;88(2):546–574. doi: 10.1002/mrm.29241
   PubMed Web of Science ®Google Scholar
• Patel SH, Poisson LM, Brat DJ, et al. T2–FLAIR mismatch, an imaging biomarker for IDH and 1p/19q status in lower-grade gliomas: a TCGA/TCIA project. Clin Cancer Res. 2017;23(20):6078–6085. doi: 10.1158/1078-0432.CCR-17-0560
   PubMed Web of Science ®Google Scholar
• Adamou A, Beltsios ET, Papanagiotou P. The T2-FLAIR mismatch sign as an imaging indicator of IDH-Mutant, 1p/19q non-codeleted lower grade gliomas: a systematic review and diagnostic accuracy meta-analysis. Diagnostics. 2021;11(9):1620. doi: 10.3390/diagnostics11091620
   Web of Science ®Google Scholar
• Juratli TA, Tummala SS, Riedl A, et al. Radiographic assessment of contrast enhancement and T2/FLAIR mismatch sign in lower grade gliomas: correlation with molecular groups. J Neurooncol. 2019;141(2):327–335. doi: 10.1007/s11060-018-03034-6
   PubMed Web of Science ®Google Scholar
• Foltyn M, Nieto Taborda KN, Neuberger U, et al. T2/FLAIR-mismatch sign for noninvasive detection of IDH-mutant 1p/19q non-codeleted gliomas: validity and pathophysiology. Neurooncol Adv. 2020;2:vdaa004. doi: 10.1093/noajnl/vdaa004
   PubMedGoogle Scholar
• Broen MPG, Smits M, Wijnenga MMJ, et al. The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation study. Neuro Oncol. 2018;20(10):1393–1399. doi: 10.1093/neuonc/noy048
   PubMed Web of Science ®Google Scholar
• Corell A, Ferreyra Vega S, Hoefling N, et al. The clinical significance of the T2-FLAIR mismatch sign in grade II and III gliomas: a population-based study. BMC Cancer. 2020;20(1):450. doi: 10.1186/s12885-020-06951-w
   PubMed Web of Science ®Google Scholar
• Pinto C, Noronha C, Taipa R, et al. T2-FLAIR mismatch sign: a roadmap of pearls and pitfalls. BJR. 2022;95(1129):20210825. doi: 10.1259/bjr.20210825
   Google Scholar
• Jain R, Johnson DR, Patel SH, et al. “Real world” use of a highly reliable imaging sign: “T2-FLAIR mismatch” for identification of IDH mutant astrocytomas. Neuro Oncol. 2020;22(7):936–943. doi: 10.1093/neuonc/noaa041
   PubMed Web of Science ®Google Scholar
• Mohammed S, Ravikumar V, Warner E, et al. Quantifying T2-FLAIR mismatch using geographically weighted regression and predicting molecular status in lower-grade gliomas. AJNR Am J Neuroradiol. 2022;43(1):33–39. doi: 10.3174/ajnr.A7341
   PubMed Web of Science ®Google Scholar
• Kinoshita M, Arita H, Takahashi M, et al. Impact of Inversion time for FLAIR acquisition on the T2-FLAIR mismatch detectability for IDH-Mutant, non-CODEL astrocytomas. Front Oncol. 2021;10:596448. doi: 10.3389/fonc.2020.596448
   PubMed Web of Science ®Google Scholar
• Li M, Ren X, Chen X, et al. Combining hyperintense FLAIR rim and radiological features in identifying IDH mutant 1p/19q non-codeleted lower-grade glioma. Eur Radiol. 2022;32(6):3869–3879. doi: 10.1007/s00330-021-08500-w
   PubMed Web of Science ®Google Scholar
• Johnson DR, Kaufmann TJ, Patel SH, et al. There is an exception to every rule—T2-FLAIR mismatch sign in gliomas. Neuroradiology. 2019;61(2):225–227. doi: 10.1007/s00234-018-2148-4
   PubMed Web of Science ®Google Scholar
• Kurokawa R, Kurokawa M, Baba A, et al. Dynamic susceptibility contrast-MRI parameters, ADC values, and the T2-FLAIR mismatch sign are useful to differentiate between H3-mutant and H3-wild-type high-grade midline glioma. Eur Radiol. 2022;32(6):3672–3682. doi: 10.1007/s00330-021-08476-7
   PubMed Web of Science ®Google Scholar
• Onishi S, Amatya VJ, Kolakshyapati M, et al. T2-FLAIR mismatch sign in dysembryoplasticneuroepithelial tumor. Eur J Radiol. 2020;126:108924. doi: 10.1016/j.ejrad.2020.108924
   PubMed Web of Science ®Google Scholar
• Song S, Wang L, Yang H, et al. Static 18F-FET PET and DSC-PWI based on hybrid PET/MR for the prediction of gliomas defined by IDH and 1p/19q status. Eur Radiol. 2021;31(6):4087–4096. doi: 10.1007/s00330-020-07470-9
   PubMed Web of Science ®Google Scholar
• Johnson DR, Diehn FE, Giannini C, et al. Genetically defined oligodendroglioma is characterized by indistinct tumor borders at MRI. AJNR Am J Neuroradiol. 2017;38(4):678–684. doi: 10.3174/ajnr.A5070
   PubMed Web of Science ®Google Scholar
• Zhao K, Sun G, Wang Q, et al. The diagnostic value of conventional MRI and CT features in the identification of the IDH1-mutant and 1p/19q co-deletion in WHO grade II gliomas. Acad Radiol. 2021;28(7):e189–e198. doi: 10.1016/j.acra.2020.03.008
   PubMed Web of Science ®Google Scholar
• Batchala PP, Muttikkal TJE, Donahue JH, et al. Neuroimaging-based classification algorithm for predicting 1p/19q-codeletion status in IDH -mutant lower grade gliomas. AJNR Am J Neuroradiol. 2019;ajnr;ajnr.A5957v1. doi: 10.3174/ajnr.A5957
   Web of Science ®Google Scholar
• Lasocki A, Gaillard F, Gorelik A, et al. MRI features can predict 1p/19q status in intracranial gliomas. AJNR Am J Neuroradiol. 2018;39(4):687–692. doi: 10.3174/ajnr.A5572
   PubMed Web of Science ®Google Scholar
• Joyner DA, Garrett J, Batchala PP, et al. MRI features predict tumor grade in isocitrate dehydrogenase (IDH)–mutant astrocytoma and oligodendroglioma. Neuroradiology. 2023;65(1):121–129. doi: 10.1007/s00234-022-03038-0
   PubMed Web of Science ®Google Scholar
• Mancini L, Casagranda S, Gautier G, et al. CEST MRI provides amide/amine surrogate biomarkers for treatment-naïve glioma sub-typing. Eur J Nucl Med Mol Imaging. 2022;49(7):2377–2391. doi: 10.1007/s00259-022-05676-1
   PubMed Web of Science ®Google Scholar
• Branzoli F, Pontoizeau C, Tchara L, et al. Cystathionine as a marker for 1p/19q codeleted gliomas by in vivo magnetic resonance spectroscopy. Neuro Oncol. 2019;21(6):765–774. doi: 10.1093/neuonc/noz031
   PubMed Web of Science ®Google Scholar
• Chakrabarty S, LaMontagne P, Shimony J, et al. MRI-based classification of IDH mutation and 1p/19q codeletion status of gliomas using a 2.5D hybrid multi-task convolutional neural network. Neurooncol Adv. 2023;5:vdad023. doi: 10.1093/noajnl/vdad023
   PubMedGoogle Scholar
• Nishikawa T, Ohka F, Aoki K, et al. Easy-to-use machine learning system for the prediction of IDH mutation and 1p/19q codeletion using MRI images of adult-type diffuse gliomas. Brain Tumor Pathol. 2023;40(2):85–92. doi: 10.1007/s10014-023-00459-4
   PubMed Web of Science ®Google Scholar
• Zulfiqar M, Yousem DM, Lai H. ADC values and prognosis of malignant astrocytomas: does lower ADC predict a worse prognosis independent of grade of tumor?—A meta-analysis. Am J Roentgenol. 2013;200(3):624–629. doi: 10.2214/AJR.12.8679
   PubMed Web of Science ®Google Scholar
• Hirai T, Murakami R, Nakamura H, et al. Prognostic value of perfusion MR imaging of high-grade astrocytomas: long-term follow-up study. AJNR Am J Neuroradiol. 2008;29(8):1505–1510. doi: 10.3174/ajnr.A1121
   PubMed Web of Science ®Google Scholar
• Danchaivijitr N, Waldman AD, Tozer DJ, et al. Low-grade gliomas: do changes in rCBV Measurements at longitudinal perfusion-weighted MR imaging predict malignant transformation? Radiology. 2008;247(1):170–178. doi: 10.1148/radiol.2471062089
   PubMed Web of Science ®Google Scholar
• Caseiras GB, Chheang S, Babb J, et al. Relative cerebral blood volume measurements of low-grade gliomas predict patient outcome in a multi-institution setting. Eur J Radiol. 2010;73(2):215–220. doi: 10.1016/j.ejrad.2008.11.005
   PubMed Web of Science ®Google Scholar
• Hattingen E, Raab P, Franz K, et al. Prognostic value of choline and creatine in WHO grade II gliomas. Neuroradiology. 2008;50(9):759–767. doi: 10.1007/s00234-008-0409-3
   PubMed Web of Science ®Google Scholar
• Singhal T, Narayanan TK, Jacobs MP, et al. 11 C-Methionine PET for grading and prognostication in gliomas: a comparison study with 18 F-FDG PET and contrast enhancement on MRI. J Nucl Med. 2012;53(11):1709–1715. doi: 10.2967/jnumed.111.102533
   PubMed Web of Science ®Google Scholar
• Wang J, Zheng X, Zhang J, et al. An MRI-based radiomics signature as a pretreatment noninvasive predictor of overall survival and chemotherapeutic benefits in lower-grade gliomas. Eur Radiol. 2021;31(4):1785–1794. doi: 10.1007/s00330-020-07581-3
   PubMed Web of Science ®Google Scholar
• Li Z, Liu P, An T, et al. Construction of a prognostic immune signature for lower grade glioma that can be recognized by MRI radiomics features to predict survival in LGG patients. Transl Oncol. 2021;14(6):101065. doi: 10.1016/j.tranon.2021.101065
   PubMed Web of Science ®Google Scholar
• Li Y, Qian Z, Xu K, et al. Radiomic features predict ki-67 expression level and survival in lower grade gliomas. J Neurooncol. 2017;135(2):317–324. doi: 10.1007/s11060-017-2576-8
   PubMed Web of Science ®Google Scholar
• Brasil Caseiras G, Ciccarelli O, Altmann DR, et al. Low-grade gliomas: six-month tumor growth predicts patient outcome better than admission tumor volume, relative Cerebral blood volume, and apparent diffusion coefficient. Radiology. 2009;253(2):505–512. doi: 10.1148/radiol.2532081623
   PubMed Web of Science ®Google Scholar
• Pallud J, Blonski M, Mandonnet E, et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for diffuse low-grade gliomas. Neuro Oncol. 2013;15(5):595–606. doi: 10.1093/neuonc/nos331
   PubMed Web of Science ®Google Scholar
• Goze C, Blonski M, Le Maistre G, et al. Imaging growth and isocitrate dehydrogenase 1 mutation are independent predictors for diffuse low-grade gliomas. Neuro Oncol. 2014;16(8):1100–1109. doi: 10.1093/neuonc/nou085
   PubMed Web of Science ®Google Scholar
• Pallud J, Mandonnet E, Duffau H, et al. Prognostic value of initial magnetic resonance imaging growth rates for World Health Organization grade II gliomas. Ann Neurol. 2006;60(3):380–383. doi: 10.1002/ana.20946
   PubMed Web of Science ®Google Scholar
• Capelle L, Fontaine D, Mandonnet E, et al. Spontaneous and therapeutic prognostic factors in adult hemispheric world Health organization grade II gliomas: a series of 1097 cases: clinical article. JNS. 2013;118(6):1157–1168. doi: 10.3171/2013.1.JNS121
   PubMed Web of Science ®Google Scholar
• Chen H, Judkins J, Thomas C, et al. Mutant IDH1 and seizures in patients with glioma. Neurology. 2017;88:1805. doi: 10.1212/WNL.0000000000003911
   PubMed Web of Science ®Google Scholar
• Audrey C, Lim K-S, Ahmad Zaki R, et al. Prevalence of seizures in brain tumor: a meta-analysis. Epilepsy Res. 2022;187:107033. doi: 10.1016/j.eplepsyres.2022.107033
   PubMed Web of Science ®Google Scholar
• Pallud J, Audureau E, Blonski M, et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain. 2014;137:449–462. doi: 10.1093/brain/awt345
   PubMed Web of Science ®Google Scholar
• Avila EK, Chamberlain M, Schiff D, et al. Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials. Neuro Oncol. 2017;19(1):12–21. doi: 10.1093/neuonc/now190
   PubMed Web of Science ®Google Scholar
• Rudà R, Bello L, Duffau H, et al. Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments. Neuro Oncol. 2012;14(suppl 4):iv55–iv64. doi: 10.1093/neuonc/nos199
   PubMed Web of Science ®Google Scholar
• Englot DJ, Berger MS, Barbaro NM, et al. Predictors of seizure freedom after resection of supratentorial low-grade gliomas: a review. J Neurosurg. 2011;115(2):240–244. doi: 10.3171/2011.3.JNS1153
   PubMed Web of Science ®Google Scholar
• Mortazavi A, Fayed I, Bachani M, et al. IDH-mutated gliomas promote epileptogenesis through d-2-hydroxyglutarate-dependent mTOR hyperactivation. Neuro Oncol. 2022;24(9):1423–1435. doi: 10.1093/neuonc/noac003
   PubMed Web of Science ®Google Scholar
• Drumm MR, Wang W, Sears TK, et al. Postoperative risk of IDH mutant glioma–associated seizures and their potential management with IDH mutant inhibitors. J Clin Invest. [Internet]. 2023;133(12). doi: 10.1172/JCI168035
   PubMed Web of Science ®Google Scholar
• Vo AH, Ambady P, Spencer D. The IDH1 inhibitor ivosidenib improved seizures in a patient with drug-resistant epilepsy from IDH1 mutant oligodendroglioma. Epilepsy Behav Rep. 2022;18:100526–100526. doi: 10.1016/j.ebr.2022.100526
   PubMedGoogle Scholar